IntrinsicIntrinsic
← All summaries

NOVANTA INC

NOVT
Financials & Chart →

Business Summary

Novanta Inc. is a leading global supplier of core technology solutions that give medical, life science, and advanced industrial original equipment manufacturers (OEMs) a competitive advantage. The company operates primarily in two end markets: the medical market and the advanced industrial market. For the year ended December 31, 2025, the medical market accounted for approximately 53% of the company's revenue, while the advanced industrial market accounted for approximately 47% of revenue. Revenue from the medical market is generally affected by hospital, life science, and other healthcare provider capital spending, growth rates of surgical procedures, changes in regulatory requirements and laws, demand levels for life science automation technology, aggregation of purchasing by healthcare networks, changes in technology requirements, timing of OEM customers' product development and new product launches, changes in customer or patient preferences, and general demographic trends. Revenue from the advanced industrial market is affected by factors including changing technology requirements and preferences of customers, productivity or quality investments in a manufacturing environment, the financial condition of customers, changes in regulatory requirements and laws, and general economic conditions. The company believes that the Purchasing Managers' Index on manufacturing activities specific to different regions around the world may provide an indication of the impact of general economic conditions on sales into the advanced industrial market.

The company encounters strong competition in virtually all the markets, applications, and technologies it serves. Competitors range from large foreign and domestic organizations that produce a comprehensive array of goods and services, to small organizations producing a limited number of highly specialized products or services for specialized applications. The competitive climate of many end market applications is characterized by rapidly evolving technology and customer demands that require continuous investments. Competitive success requires advances in technology and product performance, improved price-for-performance ratios, demonstrated increased throughput performance for customers' products, lower total cost of ownership, product quality, depth of application knowledge and expertise, reputation amongst customers, customer service and technical support, speed to market, geographical presence, and deep customer relationships. The company believes its products offer many competitive advantages and the breadth of its technologies gives deep applications knowledge to better serve customers' needs. During the year ended December 31, 2025, two OEM customers, each operating primarily in the medical end market across multiple product lines, represented approximately 12% and 11% , respectively, of consolidated revenue. The top ten customers accounted for approximately 42% of sales for the year ended December 31, 2025.

The company generates revenue by designing, manufacturing, and marketing core technology solutions, including components and sub-systems, to OEM customers in the medical and advanced industrial markets. The vast majority of product offerings are sold to OEM customers, with the majority sold directly utilizing a highly technical sales force, and some sold indirectly through resellers and distributors. Revenue is recognized when control of promised goods or services is transferred to customers, which generally occurs upon shipment when title and risk of loss pass to the customer. The vast majority of revenue is generated from the sale of distinct products and is recognized at a point in time, upon shipment, rather than over time. Professional services, generally for maintenance, repair, and engineering services, are less than 3% of consolidated revenue. The company occasionally sells separately priced non-standard/extended warranty services or preventative maintenance plans, with revenue recognized ratably over the terms of the service plans. The standard warranty period is typically 12 months to 36 months .

The Automation Enabling Technologies segment designs, manufactures and markets laser beam steering and scanning solutions, laser sources, robotic and precision motion, robotic end-of-arm tooling, and bearing spindles to customers worldwide. The segment serves highly demanding applications for advanced industrial processes, advanced industrial and medical robotics, other medical and life science automation applications, and medical laser procedures such as ophthalmology applications. For the year ended December 31, 2025, the Automation Enabling Technologies segment reported external revenue of $500.8 million , a gross profit margin of 47.8% , and operating profit of $114.5 million . The segment is comprised of product lines including Laser Beam Steering and Scanning Solutions, Laser Sources, Robotic and Precision Motion, Robotic end-of-arm tooling, and Air Bearing Spindles. The segment's revenue in 2025 increased by $10.2 million , or 2.1% , versus 2024, primarily due to a $30.3 million increase in revenue from robotics and automation products, partially offset by a $20.0 million decline in revenue from precision manufacturing products.

The Medical Solutions segment designs, manufactures and markets a range of medical grade technologies, including medical insufflators and endoscopic pumps and related disposables, imaging, identification and RFID solutions, advanced motion control solutions, light engines, and integrated operating room technologies. For the year ended December 31, 2025, the Medical Solutions segment reported external revenue of $479.8 million , a gross profit margin of 41.6% , and operating profit of $51.2 million . The segment is comprised of product lines including Medical Insufflators, Endoscopic Pumps and related disposables, Imaging, Identification and RFID Solutions, Advanced Motion Control Solutions, Light Engines, and Integrated operating room technologies. The segment's revenue in 2025 increased $21.1 million , or 4.6% , versus 2024, primarily driven by a $33.7 million increase in revenue from advanced surgery products, partially offset by a $12.6 million decline in precision medicine products.

On November 12, 2025, the company issued 12,650,000 of its 6.50% tangible equity units at $50.00 per Unit, via a registered public offering, recording net proceeds of $613.1 million . On June 27, 2025, the company entered into the Fourth Amended and Restated Credit Agreement, which provides for an aggregate credit facility of approximately $1.0 billion , comprised of a €65.3 million euro-denominated 5-year term loan facility, a $75.0 million U.S. dollar denominated 5-year term loan facility, and an $850.0 million 5-year revolving credit facility. On April 8, 2025, the company acquired 100% of the outstanding stock of Keonn Technologies, S.L. for a purchase price of €64.8 million ($71.0 million) , net of cash acquired, including €4.1 million ($4.5 million) estimated fair value of contingent consideration and €2.0 million ($2.2 million) related to a purchase price holdback. The purchase includes up to €20.0 million ($21.9 million) in contingent consideration payable upon the achievement of certain revenue targets through December 2027. In addition, the company granted equity totaling €9.0 million ($9.9 million) to Keonn employees. During the year ended December 31, 2025, the company repurchased 357 thousand shares for an aggregate purchase price of $39.3 million at an average price of $110.17 per share under the 2020 Repurchase Plan. In September 2025, the Board approved the 2025 Repurchase Plan authorizing the repurchase of $200.0 million worth of common shares.

Total revenue for 2025 was $980.6 million , an increase of $31.4 million , or 3.3% , versus 2024. The net effect of the current year acquisition resulted in an increase in revenue of $21.8 million , or 2.3% . Foreign currency exchange rate favorably impacted revenue by $14.6 million or 1.5% in 2025. Operating income for 2025 was $94.0 million , a decrease of $16.6 million , or 15.0% , versus 2024. Net income was $53.8 million for 2025, compared to $64.1 million for 2024. Basic earnings per common share of $1.47 in 2025 decreased $0.31 from basic EPS of $1.78 in 2024. Diluted earnings per common share of $1.47 in 2025 decreased $0.30 from diluted EPS of $1.77 in 2024.

Business Outlook

The company expects to use approximately $20 million to $25 million in 2026 for capital expenditures related to investments in new property, plant and equipment for its existing businesses.

The company's strategy includes increasing penetration of high growth advanced industrial applications, such as laser materials processing, intelligent end-of-arm robotic technology solutions, robotics, laser additive manufacturing, automation and metrology, by working closely with OEM customers to launch application specific products. The company also aims to improve its business mix to increase medical sales as a percentage of total revenue by introducing new products aimed at attractive medical applications, such as minimally invasive and robotic surgery, ophthalmology, patient monitoring, drug delivery, clinical laboratory testing and life science equipment, deepening key account management relationships with leading medical equipment manufacturers, and pursuing complementary medical technology acquisitions. The company expects to broaden its portfolio of enabling proprietary technologies and capabilities through increased investment in new product development and investments in application development to further penetrate existing customers while expanding the applicability of its solutions to new markets.

The company's strategy includes broadening its product and service offerings through the acquisition of innovative and complementary technologies and solutions in medical and advanced industrial technology applications. The acquisition of Keonn Technologies, S.L., a Barcelona, Spain-based leader in Radio-Frequency Identification (RFID) solutions, was completed on April 8, 2025, and is included in the Medical Solutions segment. The purchase includes up to €20.0 million ($21.9 million) in contingent consideration payable upon the achievement of certain revenue targets through December 2027. The company expects to continue to make acquisitions in the future as part of its business strategy.

The company's strategy includes strengthening operational performance to expand profit margins and enhance customer satisfaction by deploying lean manufacturing principles and advancing strategic sourcing initiatives across major production sites, while regionalizing its manufacturing footprint and establishing manufacturing centers of excellence to achieve greater efficiency and reduce overall production complexity. The company recorded restructuring, acquisition and related costs of $22.7 million in 2025, versus $13.7 million in 2024, with the increase primarily attributable to restructuring costs incurred in connection with the 2025 restructuring program undertaken to regionalize the manufacturing footprint and establish manufacturing centers of excellence.

The company's strategy includes expanding sales and marketing channels to reach new target customers. The company sells its products globally, primarily through its direct sales force, and also uses distributors, including manufacturers' representatives, to either augment its selling effort or serve a local market where it has no direct sales force. The company maintains and continues to invest in a number of application centers around the world, where application experts work closely with customers on integrating and using solutions in their equipment. The company currently maintains service and application centers in the United States, Europe and Asia.

The company's strategy includes advancing a people first culture that promotes a growth mindset, cohesive and engaged teams, and continuous employee development to enable long-term organizational excellence. As of December 31, 2025, the company employed approximately 3,000 people, of which approximately 36% were in the United States, 55% in Europe, and 9% in Asia. The company's engineering teams consist of approximately 600 employees. The company utilizes survey feedback mechanisms to measure employee engagement and organizational health, and its employee satisfaction score in the most recent survey in February 2025 was 97% of the benchmark score, an improvement of 2 percentage points compared to 2024.

The company faces structural headwinds from economic and political conditions, including inflation, supply chain disruptions, business slowdowns, labor shortages, market volatility, and new and proposed tariffs announced by the U.S. Presidential Administration. Uncertainty remains about overall macroeconomic conditions due to geopolitical tensions and changes in trade policies. Economic tensions and changes in trade policies, such as higher tariffs, retaliatory measures, renegotiated free trade agreements, changes in government funding, and the ongoing impact from prolonged inflationary pressures have impacted the global market for the company's products and the related cost to manufacture. The company also faces risks from changes in foreign currency rates, as a portion of its revenue is derived from European and Asian operations and includes transactions in Euros, British Pounds, Chinese Yuan and Japanese Yen.

The company faces constraints from extensive and dynamic medical device regulations, which may impede or hinder the approval, certification or sale of its products. Some of the company's products, and the related development, manufacturing and commercialization activities are subject to extensive and rigorous regulation by the FDA pursuant to the Federal Food, Drug, and Cosmetic Act, and by comparable or other regulatory agencies and governing bodies in the U.S. and around the world. In the EU, medical devices must comply with the EU Medical Devices Regulation, including the general safety and performance requirements. The company also faces risks related to healthcare industry cost containment and healthcare reform measures that could result in reduced sales of its products, as several of its customers rely on third party payors to reimburse some or all of the cost of the procedures in which its products are used.

Risk Factors

The company's results of operations could be adversely affected by economic and political conditions and the effects of these conditions on customers' businesses, capital expenditures and levels of business activities. A severe and/or prolonged overall economic downturn or a negative or uncertain political climate could lead to weaknesses in the company's end markets. The company faces risks from changes in foreign currency rates, as a portion of its revenue is derived from European and Asian operations and includes transactions in Euros, British Pounds, Chinese Yuan and Japanese Yen. The company is subject to extensive and dynamic medical device regulations, which may impede or hinder the approval, certification or sale of its products and may result in the recall or seizure of previously approved or certified products. The company's reliance upon OEM customers subjects it to credit, inventory, and business failure risks beyond its control, and the loss of sales, or significant reductions in orders from, any major customers may have a material adverse effect. The company's top ten customers accounted for approximately 42% of its sales for the year ended December 31, 2025. The company had $828.1 million of net intangible assets, including goodwill, as of December 31, 2025, and adverse changes in the business or assumptions used to determine fair value may result in an impairment of these assets.

Management Priorities

Management's discussion and analysis emphasizes the company's strategy to drive sustainable, profitable growth through a disciplined focus on its diversified business model of providing proprietary technology solutions to long life-cycle OEM customer platforms in attractive medical and advanced industrial niche markets. Key themes include improving business mix to increase medical sales as a percentage of total revenue, increasing penetration of high growth advanced industrial applications, broadening the portfolio of enabling proprietary technologies through increased investment in new product development, broadening product and service offerings through acquisitions, expanding sales and marketing channels, strengthening operational performance to expand profit margins by deploying lean manufacturing principles and regionalizing the manufacturing footprint, and advancing a people first culture. Management notes that total revenue for 2025 was $980.6 million , an increase of $31.4 million , or 3.3% , versus 2024, and that operating income for 2025 was $94.0 million , a decrease of $16.6 million , or 15.0% , versus 2024. Management states that the company expects to use approximately $20 million to $25 million in 2026 for capital expenditures.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — End Markets
  2. [2] Item 7, MD&A — End Markets
  3. [3] Item 1, Business — Customers
  4. [4] Item 1, Business — Customers
  5. [5] Item 1A, Risk Factors
  6. [6] Item 8, Note 2 — Revenue Recognition
  7. [7] Item 8, Note 2 — Revenue Recognition
  8. [8] Item 1, Business — Segments
  9. [9] Item 1, Business — Segments
  10. [10] Item 1, Business — Segments
  11. [11] Item 7, MD&A — Automation Enabling Technologies
  12. [12] Item 7, MD&A — Automation Enabling Technologies
  13. [13] Item 7, MD&A — Automation Enabling Technologies
  14. [14] Item 7, MD&A — Automation Enabling Technologies
  15. [15] Item 1, Business — Segments
  16. [16] Item 1, Business — Segments
  17. [17] Item 1, Business — Segments
  18. [18] Item 7, MD&A — Medical Solutions
  19. [19] Item 7, MD&A — Medical Solutions
  20. [20] Item 7, MD&A — Medical Solutions
  21. [21] Item 7, MD&A — Medical Solutions
  22. [22] Item 7, MD&A — Tangible Equity Units Issuance
  23. [23] Item 7, MD&A — Tangible Equity Units Issuance
  24. [24] Item 7, MD&A — Tangible Equity Units Issuance
  25. [25] Item 7, MD&A — Fourth Amended and Restated Credit Agreement
  26. [26] Item 7, MD&A — Fourth Amended and Restated Credit Agreement
  27. [27] Item 7, MD&A — Fourth Amended and Restated Credit Agreement
  28. [28] Item 7, MD&A — Fourth Amended and Restated Credit Agreement
  29. [29] Item 7, MD&A — Acquisition of Keonn Technologies, S.L.
  30. [30] Item 7, MD&A — Acquisition of Keonn Technologies, S.L.
  31. [31] Item 7, MD&A — Acquisition of Keonn Technologies, S.L.
  32. [32] Item 7, MD&A — Acquisition of Keonn Technologies, S.L.
  33. [33] Item 7, MD&A — Acquisition of Keonn Technologies, S.L.
  34. [34] Item 7, MD&A — Share Repurchase Plans
  35. [35] Item 7, MD&A — Share Repurchase Plans
  36. [36] Item 7, MD&A — Share Repurchase Plans
  37. [37] Item 7, MD&A — Share Repurchase Plans
  38. [38] Item 7, MD&A — Overview of Financial Results
  39. [39] Item 7, MD&A — Overview of Financial Results
  40. [40] Item 7, MD&A — Overview of Financial Results
  41. [41] Item 7, MD&A — Overview of Financial Results
  42. [42] Item 7, MD&A — Overview of Financial Results
  43. [43] Item 7, MD&A — Overview of Financial Results
  44. [44] Item 7, MD&A — Overview of Financial Results
  45. [45] Item 7, MD&A — Overview of Financial Results
  46. [46] Item 7, MD&A — Overview of Financial Results
  47. [47] Item 7, MD&A — Overview of Financial Results
  48. [48] Item 7, MD&A — Net Income
  49. [49] Item 7, MD&A — Net Income
  50. [50] Item 7, MD&A — Overview of Financial Results
  51. [51] Item 7, MD&A — Overview of Financial Results
  52. [52] Item 7, MD&A — Overview of Financial Results
  53. [53] Item 7, MD&A — Overview of Financial Results
  54. [54] Item 7, MD&A — Overview of Financial Results
  55. [55] Item 7, MD&A — Overview of Financial Results
  56. [56] Item 7, MD&A — Investing Cash Flows
  57. [57] Item 7, MD&A — Acquisition of Keonn Technologies, S.L.
  58. [58] Item 7, MD&A — Restructuring, Acquisition and Related Costs
  59. [59] Item 7, MD&A — Restructuring, Acquisition and Related Costs
  60. [60] Item 1, Business — Human Capital
  61. [61] Item 1, Business — Human Capital
  62. [62] Item 1, Business — Human Capital
  63. [63] Item 1, Business — Human Capital
  64. [64] Item 1, Business — Human Capital
  65. [65] Item 1, Business — Human Capital
  66. [66] Item 1, Business — Human Capital
  67. [67] Item 1A, Risk Factors
  68. [68] Item 1A, Risk Factors
  69. [69] Item 7, MD&A — Overview of Financial Results
  70. [70] Item 7, MD&A — Overview of Financial Results
  71. [71] Item 7, MD&A — Overview of Financial Results
  72. [72] Item 7, MD&A — Overview of Financial Results
  73. [73] Item 7, MD&A — Overview of Financial Results
  74. [74] Item 7, MD&A — Overview of Financial Results
  75. [75] Item 7, MD&A — Investing Cash Flows
  76. [76] Item 8, Consolidated Statements of Operations
  77. [77] Item 8, Consolidated Statements of Operations
  78. [78] Item 8, Consolidated Statements of Operations
  79. [79] Item 8, Consolidated Statements of Operations
  80. [80] Item 8, Consolidated Statements of Operations
  81. [81] Item 8, Consolidated Statements of Operations
  82. [82] Item 8, Consolidated Statements of Operations
  83. [83] Item 8, Consolidated Statements of Operations
  84. [84] Item 7, MD&A — Gross Profit
  85. [85] Item 8, Consolidated Statements of Operations
  86. [86] Item 8, Consolidated Statements of Operations
  87. [87] Item 8, Consolidated Statements of Cash Flows
  88. [88] Item 8, Consolidated Statements of Cash Flows
  89. [89] Item 8, Consolidated Balance Sheets
  90. [90] Item 8, Consolidated Balance Sheets
  91. [91] Item 7, MD&A — Liquidity and Capital Resources
  92. [92] Item 8, Consolidated Balance Sheets
  93. [93] Item 7, MD&A — Operating Income (Loss) by Segment
  94. [94] Item 7, MD&A — Operating Income (Loss) by Segment
  95. [95] Item 7, MD&A — Operating Income (Loss) by Segment
  96. [96] Item 7, MD&A — Operating Income (Loss) by Segment
  97. [97] Item 7, MD&A — Restructuring, Acquisition and Related Costs
  98. [98] Item 7, MD&A — Restructuring, Acquisition and Related Costs
  99. [99] Item 7, MD&A — Income Tax Provision
  100. [100] Item 7, MD&A — Income Tax Provision
  101. [101] Item 7, MD&A — Income Tax Provision
  102. [102] Item 7, MD&A — Income Tax Provision

Analysis on 6/10/2026